Morepen Laboratories – Steady Growth with Modest Profit Improvement

Morepen Laboratories reported a stable quarterly performance with decent growth in sales and operating profit. • Sales: ↑ 13.47% YoY to ₹457.57 crore (vs ₹403.25 crore in Dec 2024) • EBITDA: ↑ 25.71% YoY to ₹45.82 crore (vs ₹36.45 crore) • Net Profit: ↑ 3.57% YoY to ₹23.50 crore (vs ₹22.69 crore) • EPS: ↑ slightly to ₹0.43 (vs ₹0.41) The company is showing steady revenue and operating growth, but profit growth is slow, and the stock price has been under pressure recently.